

57. The process of any one of claims 1 to 56, wherein the antibody contained in the first antibody preparation is 99.8% pure prior to step (a).
58. The process of any one of claims 1 to 57, wherein level of aggregate contaminants in the third antibody preparation is less than 2 weight percent.
59. The process of any one of claims 1 to 58, wherein the ~~pharmaceutical~~antibody composition is suitable for therapeutic administration by intramuscular or intravenous administration.
60. The process of claim 59, wherein the therapeutic administration is to a human.
61. The process of any one of claims 1 to 60, wherein the first antibody preparation is purified antibody preparation.
62. The process of any one of claims 1 to 61, wherein the antibody is anti-IgE antibody rhuMab E25 or an antigen-binding fragment thereof.